4D Molecular Therapeutics, Inc. (FDMT) vs Verastem, Inc. (VSTM)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and Verastem, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.73HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
VSTM
Verastem, Inc.
$7.81HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT
Total return — FDMT vs VSTM
growth of $100 · dividends reinvested · last 6yFDMT -68.1% (-17.3%/yr)VSTM -71.5% (-18.9%/yr)FDMT compounded faster over this window
FDMT VSTM
FDMT vs VSTM: by the numbers
- •VSTM is the larger company ($686M vs $665M market cap).
- •Both run net losses; FDMT's is the smaller (-194.74% vs -231.59% net margin).
- •FDMT grew revenue faster over the past five years (31.93% vs -18.98% CAGR).
Metrics side by side
Valuation
| Metric | FDMT | VSTM |
|---|---|---|
| P/S ratio | 7.23 | 7.84 |
| P/B ratio | 1.63 | 13.72 |
Profitability
| Metric | FDMT | VSTM |
|---|---|---|
| Gross margin | 91.05% | 86.69% |
| Operating margin | -187.24% | -550.33% |
| Net margin | -194.74% | -231.59% |
| ROE | -43.95% | -405.51% |
| ROIC | -44.30% | -118.97% |
Growth (annualized)
| Metric | FDMT | VSTM |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | -18.98% |
| Total return CAGR (5Y) | -13.08% | -25.22% |
Frequently asked
- Which has grown faster, FDMT or VSTM?
- Over the past five years, FDMT grew revenue faster — FDMT at a 31.93% CAGR versus VSTM at -18.98%.
- How have FDMT and VSTM total returns compared?
- Over the past 5 years, FDMT delivered -13.08% and VSTM delivered -25.22% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
4D Molecular Therapeutics ROEVerastem ROE4D Molecular Therapeutics operating marginVerastem operating margin4D Molecular Therapeutics revenue growthVerastem revenue growth4D Molecular Therapeutics free cash flowVerastem free cash flow
4D Molecular Therapeutics & Verastem appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.